1-20 of 28
Senthil Damodaran
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor–Positive Metastatic Breast Cancers

Juliana Navarro-Yepes, Nicole M. Kettner, Xiayu Rao, Cassandra Santaella Bishop, Tuyen N. Bui, Hannah F. Wingate, Akshara Singareeka Raghavendra, Yan Wang, Jing Wang, Aysegul A. Sahin, Funda Meric-Bernstam, Kelly K. Hunt, Senthil Damodaran, Debu Tripathy, Khandan Keyomarsi
Journal: Cancer Research
Cancer Res OF1–OF20.
https://doi.org/10.1158/0008-5472.CAN-23-0705
Published: 11 September 2023
View article titled, Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor–Positive Metastatic Breast Cancers
Open the PDF for Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor–Positive Metastatic Breast Cancers in another window
Includes: Supplementary data
Journal Articles

Abstract CT107: Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid Tumors

Blessie Elizabeth Nelson, Filip Janku, Siqing Fu, Ecaterina I. Dumbrava, David S. Hong, Daniel Karp, Aung Naing, Jordi Rodon, Apostolia Tsimberidou, Rodabe N. Amaria, Anthony Conley, Senthil Damodaran, Kanwal P. Raghav, Brent L. Kreider, David Tung, Mary Varterasian, Khashayarsha Khazaie, Sarina Piha-Paul
Journal: Cancer Research
Cancer Res (2023) 83 (8_Supplement): CT107.
https://doi.org/10.1158/1538-7445.AM2023-CT107
Published: 14 April 2023
View article titled, Abstract CT107: Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid Tumors
Journal Articles

Abstract P3-02-03: A phase Ib trial of bintrafusp alfa and eribulin in patients with metastatic triple negative breast cancer (TNBC)

Senthil Damodaran, Diane Liu, Jill Schwartz, Vicente Valero, David Ramirez, Sadia Saleem, Naoto T. Ueno, Nuhad K. Ibrahim, Meghan S. Karuturi, Rashmi K. Murthy, Stacy Moulder, Jennifer K. Litton
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): P3-02-03.
https://doi.org/10.1158/1538-7445.SABCS22-P3-02-03
Published: 01 March 2023
View article titled, Abstract P3-02-03: A phase Ib trial of bintrafusp alfa and eribulin in patients with metastatic triple negative breast cancer (TNBC)
Journal Articles

Abstract OT1-11-01: Phase II study of talazoparib, a PARP inhibitor, in somatic BRCA1/2 mutant metastatic breast cancer identified by cell-free DNA or tumor tissue genotyping

Neelima Vidula, Senthil Damodaran, Erica L. Blouch, Nora Horick, Nathan Royce Ruffle-Deignan, Manali Bhave, Ami N. Shah, Leticia Varella, Vandana Abramson, Joseph Sparano, Leif Ellisen, Ishraq Alim, Harry Ostrer, Hope Rugo, Aditya Bardia
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): OT1-11-01.
https://doi.org/10.1158/1538-7445.SABCS22-OT1-11-01
Published: 01 March 2023
View article titled, Abstract OT1-11-01: Phase II study of talazoparib, a PARP inhibitor, in somatic BRCA1/2 mutant metastatic breast cancer identified by cell-free DNA or tumor tissue genotyping
Journal Articles

Abstract P5-05-02: Estrogen receptor 1 (ESR1) mutations in circulating tumor DNA (ctDNA) from patients with ER+/HER2- metastatic breast cancer (mBC) treated with lasofoxifene plus abemaciclib in the ELAINE 2 study

Senthil Damodaran, Halle Moore, Ciara C. O’Sullivan, Paul V. Plourde, Gary Riordan, Hillary S. Sloane, Debu Tripathy, Dominic Carroll, David J Portman
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): P5-05-02.
https://doi.org/10.1158/1538-7445.SABCS22-P5-05-02
Published: 01 March 2023
View article titled, Abstract P5-05-02: Estrogen receptor 1 (ESR1) mutations in circulating tumor DNA (ctDNA) from patients with ER+/HER2- metastatic breast cancer (mBC) treated with lasofoxifene plus abemaciclib in the ELAINE 2 study
Journal Articles

Abstract PD13-08: PD13-08 Phase 1 TROPION-PanTumor01 Study Evaluating Datopotamab Deruxtecan (Dato-DXd) in Unresectable or Metastatic Hormone Receptor–Positive/HER2–Negative Breast Cancer (BC)

Funda Meric-Bernstam, Ian Krop, Dejan Juric, Takahiro Kogawa, Erika Hamilton, Alexander I. Spira, Toru Mukohara, Takuya Tsunoda, Senthil Damodaran, Jonathan Greenberg, Wen Gu, Fumiaki Kobayashi, Hong Zebger-Gong, Yui Kawasaki, Rie Wong, Aditya Bardia
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): PD13-08.
https://doi.org/10.1158/1538-7445.SABCS22-PD13-08
Published: 01 March 2023
View article titled, Abstract PD13-08: PD13-08 Phase 1 TROPION-PanTumor01 Study Evaluating Datopotamab Deruxtecan (Dato-DXd) in Unresectable or Metastatic Hormone Receptor–Positive/HER2–Negative Breast Cancer (BC)
Journal Articles

Abstract HER2-01: HER2-01 Clinical and Molecular Characteristics of HER2-low/zero Early Stage Triple-Negative Breast Cancer

Clinton Yam, Ziyi Li, Anil Korkut, Wencai Ma, Elisabeth Kong, Holly A. Hill, Hussein Abbas, Sausan Abouharb, Beatriz Adrada, Banu K. Arun, Carlos H. Barcenas, Ajit Bisen, Daniel Booser, Aman Buzdar, Rosalind Candelaria, Junjie Chen, Alyson Clayborn, Senthil Damodaran, Qingqing Ding, Haven Garber, Gabriel N. Hortobagyi, Kelly K. Hunt, Nuhad K. Ibrahim, Adaeze Iheme, Meghan S. Karuturi, Kimberly Koenig, Rachel M. Layman, Jangsoon Lee, Jennifer K. Litton, Melissa Mitchell, Giancarlo Moscol, Jason Mouabbi, Rashmi K. Murthy, Oluchi Oke, Paula Pohlmann, David Ramirez, Elizabeth Ravenberg, Sadia Saleem, Mediget Teshome, Vicente Valero, Jason White, Madison Williams, Wendy Woodward, Chasity Yajima, Naoto T. Ueno, Ken Chen, Gaiane Rauch, Lei Huo, Debu Tripathy
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): HER2-01.
https://doi.org/10.1158/1538-7445.SABCS22-HER2-01
Published: 01 March 2023
View article titled, Abstract HER2-01: HER2-01 Clinical and Molecular Characteristics of HER2-low/zero Early Stage Triple-Negative Breast Cancer
Journal Articles

Abstract 1791: Epigenetically upregulating TROP2 enhances therapeutic efficacy of TROP2 ADC sacitizumab govitecan

Ming Zhao, Timothy P. DiPeri, Gabriela Raso, Yasmeen Q. Rizvi, Xiaofeng Zheng, Kurt Evans, Argun Akcakanat, Fei Yang, Debu Tripathy, Ecaterina Ileana Dumbrava, Senthil Damodaran, Funda Meric-Bernstam
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 1791.
https://doi.org/10.1158/1538-7445.AM2022-1791
Published: 15 June 2022
View article titled, Abstract 1791: Epigenetically upregulating TROP2 enhances therapeutic efficacy of TROP2 ADC sacitizumab govitecan
Journal Articles

Abstract 1798: Mechanisms of acquired resistance to palbociclib reveals pathways of response to abemaciclib

Juliana Navarro-Yepes, Nicole M. Kettner, Tuyen Bui, Akshara S. Raghavendra, Xiayu Rao, Jing Wang, Aysegul Sahin, Senthil Damodaran, Debasish Tripathy, Kelly K. Hunt, Khandan Keyomarsi
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 1798.
https://doi.org/10.1158/1538-7445.AM2022-1798
Published: 15 June 2022
View article titled, Abstract 1798: Mechanisms of acquired resistance to palbociclib reveals pathways of response to abemaciclib
Journal Articles

Abstract 1210: Resolving clonal substructure from single cell genomic data in primary and metastatic tumors using CopyKit

Darlan Conterno Minussi, Junke Wang, Aislyn Schalck, Yun Yan, Hua-Jun Wu, Cheng Peng, Min Hu, Emi Sei, Mary Edgerton, Hui Chen, Alejandro Contreras, David Hui, Senthil Damodaran, Scott Kopetz, Bora Lim, Nicholas Navin
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 1210.
https://doi.org/10.1158/1538-7445.AM2022-1210
Published: 15 June 2022
View article titled, Abstract 1210: Resolving clonal substructure from single cell genomic data in primary and metastatic tumors using CopyKit
Journal Articles

Abstract 1768: Anti-tumor activity and biomarker analysis for datopotamab deruxtecan in breast cancer PDX models

Erkan Yuca, Kurt Evans, Argun Akcakanat, Gabriela Raso, Yasmeen Q. Rizvi, Fei Yang, Lauren Byers, Senthil Damodaran, Okajima Daisuke, Funda Meric-Bernstam
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 1768.
https://doi.org/10.1158/1538-7445.AM2022-1768
Published: 15 June 2022
View article titled, Abstract 1768: Anti-tumor activity and biomarker analysis for datopotamab deruxtecan in breast cancer PDX models
Journal Articles

Abstract PD11-06: Radiomics model based on magnetic resonance image compilation (MagIC) as early predictor of pathologic complete response to neoadjuvant systemic therapy in triple-negative breast cancer

Nabil Elshafeey, Ken-Pin Hwang, Beatriz Elena Adrada, Rosalind Pitpitan Candelaria, Medine Boge, Rania M Mahmoud, Huiqin Chen, Jia Sun, Wei Yang, Aikaterini Kotrotsou, Benjamin C Musall, Jong Bum Son, Gary J Whitman, Jessica Leung, Huong Le-Petross, Lumarie Santiago, Deanna Lynn Lane, Marion Elizabeth Scoggins, David Allen Spak, Mary Saber Guirguis, Miral Mahesh Patel, Frances Perez, Abeer H Abdelhafez, Jason B White, Lei Huo, Elizabeth Ravenberg, Wei Peng, Alastair Thompson, Senthil Damodaran, Debu Tripathy, Stacey L Moulder, Clinton Yam, Mark David Pagel, Jingfei Ma, Gaiane Margishvili Rauch
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): PD11-06.
https://doi.org/10.1158/1538-7445.SABCS21-PD11-06
Published: 15 February 2022
View article titled, Abstract PD11-06: Radiomics model based on magnetic resonance image compilation (MagIC) as early predictor of pathologic complete response to neoadjuvant systemic therapy in triple-negative breast cancer
Journal Articles

Abstract P1-18-35: Futibatinib in combination with fulvestrant in patients with metastatic breast cancer (MBC) harboring high-level FGFR1 amplification: Preliminary data from a phase 2 study

Senthil Damodaran, Nisha Unni, Karthik V. Giridhar, Brooke Daniel, Sacha Howell, Luis Costa, Marta Ferreira, Masashi Shimura, Gareth Tomlinson, Maciej Gil, Nicholas Turner
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P1-18-35.
https://doi.org/10.1158/1538-7445.SABCS21-P1-18-35
Published: 15 February 2022
View article titled, Abstract P1-18-35: Futibatinib in combination with fulvestrant in patients with metastatic breast cancer (MBC) harboring high-level <em>FGFR1</em> amplification: Preliminary data from a phase 2 study
Journal Articles

Abstract GS1-05: Datopotamab deruxtecan in advanced/metastatic HER2- breast cancer: Results from the phase 1 TROPION-PanTumor01 study

Ian Krop, Dejan Juric, Toshio Shimizu, Anthony Tolcher, Alexander Spira, Toru Mukohara, Aaron E. Lisberg, Takahiro Kogawa, Kyriakos P. Papadopoulos, Erika Hamilton, Senthil Damodaran, Jonathan Greenberg, Wen Gu, Fumiaki Kobayashi, Ferdinand Guevara, Takahiro Jikoh, Yui Kawasaki, Funda Meric-Bernstam, Aditya Bardia
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): GS1-05.
https://doi.org/10.1158/1538-7445.SABCS21-GS1-05
Published: 15 February 2022
View article titled, Abstract GS1-05: Datopotamab deruxtecan in advanced/metastatic HER2- breast cancer: Results from the phase 1 TROPION-PanTumor01 study
Journal Articles

Abstract OT2-24-03: Phase II study of a PARP inhibitor in metastatic breast cancer with somaticBRCA1/2mutations identified by cell-free DNA: Genotyping based clinical trial

Neelima Vidula, Erica Blouch, Erin Basile, Nathan Royce Ruffle-Deignan, Nora Horick, Senthil Damodaran, Alvaro Moreno Aspitia, Manali Bhave, Ami Shah, Minetta C. Liu, Joseph Sparano, Harry Ostrer, Hope Rugo, Leif W. Ellisen, Aditya Bardia
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): OT2-24-03.
https://doi.org/10.1158/1538-7445.SABCS21-OT2-24-03
Published: 15 February 2022
View article titled, Abstract OT2-24-03: Phase II study of a PARP inhibitor in metastatic breast cancer with somatic<em>BRCA1/2</em>mutations identified by cell-free DNA: Genotyping based clinical trial
Journal Articles

Abstract P1-19-01: Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2- metastatic breast cancer patients compared to endocrine therapy alone - A large institutional study

Akshara Singareeka Raghavendra, Min Jin Ha, Nicole M. Kettner, Senthil Damodaran, Rachel Layman, Kelly K Hunt, Yu Shen, Debu Tripathy, Khandan Keyomarsi
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P1-19-01.
https://doi.org/10.1158/1538-7445.SABCS21-P1-19-01
Published: 15 February 2022
View article titled, Abstract P1-19-01: Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2- metastatic breast cancer patients compared to endocrine therapy alone - A large institutional study
Journal Articles

Abstract P5-08-12: Efficacy of futibatinib, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in breast cancer models with FGFR alterations

Turcin Saridogan, Argun Akcakanat, Ming Zhao, Kurt W. Evans, Erkan Yuca, Stephen Scott, Bryce P. Kirby, Xiaofeng Zheng, Senthil Damodaran, Funda Meric-Bernstam
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P5-08-12.
https://doi.org/10.1158/1538-7445.SABCS21-P5-08-12
Published: 15 February 2022
View article titled, Abstract P5-08-12: Efficacy of futibatinib, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in breast cancer models with FGFR alterations
Journal Articles

Estrogen Receptor: A Paradigm for Targeted Therapy

Senthil Damodaran, Gabriel N. Hortobagyi
Journal: Cancer Research
Cancer Res (2021) 81 (21): 5396–5398.
https://doi.org/10.1158/0008-5472.CAN-21-3200
Published: 01 November 2021
View article titled, Estrogen Receptor: A Paradigm for Targeted Therapy
Open the PDF for Estrogen Receptor: A Paradigm for Targeted Therapy in another window
Journal Articles

Abstract PS18-04: Prospective evaluation of patients with metaplastic (Mp) triple negative breast cancer (TNBC): Molecular characteristics and outcomes with neoadjuvant therapy (NAT)

Nour Abuhadra, Clinton Yam, Ryan Sun, Lei Huo, Jason White, Elizabeth Ravenberg, Beatriz Adrada, Aysegul Sahin, Jennifer Litton, Bora Lim, Naoto T Ueno, Banu Arun, Debu Tripathy, Senthil Damodaran, Rashmi Murthy, Vicente Valero, Gabriel Hortobagyi, Nuhad Ibrahim, Alastair Thompson, Anthony Lucci, Elizabeth Mittendorf, Stacy Moulder, Jeffrey Chang
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): PS18-04.
https://doi.org/10.1158/1538-7445.SABCS20-PS18-04
Published: 15 February 2021
View article titled, Abstract PS18-04: Prospective evaluation of patients with metaplastic (Mp) triple negative breast cancer (TNBC): Molecular characteristics and outcomes with neoadjuvant therapy (NAT)
Journal Articles

Abstract OT-34-01: Phase Ib/II trial of copanlisib in combination with trastuzumab and pertuzumab after induction treatment of HER2 positive metastatic breast cancer with PIK3CA mutation or PTEN mutation

Senthil Damodaran, Rashmi K Murthy, Maliha Nusrat, Babita Saigal, Samantha C Trager, Debu Tripathy, Funda Meric-Bernstam
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): OT-34-01.
https://doi.org/10.1158/1538-7445.SABCS20-OT-34-01
Published: 15 February 2021
View article titled, Abstract OT-34-01: Phase Ib/II trial of copanlisib in combination with trastuzumab and pertuzumab after induction treatment of HER2 positive metastatic breast cancer with <em>PIK3CA</em> mutation or <em>PTEN</em> mutation